Singapore-based firm to start human trials for Covid-19 treatment

Tychan, Singaporean biotechnology firm,  will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19

The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.

TY027 is being explored for its ability to slow down the progression of Covid-19 and speed up recovery, and its potential to provide temporary protection against infection

It is said that if phase one is successful, Tychan will seek approval for the antibody to be administered to a larger population of volunteer patients in subsequent trials.